Article

Sustained-release implant promising for long-term IOP reduction

E. Randy Craven, MD, shares results from a phase 1/2 study involving an intracameral bimatoprost sustained-release implant. 

E. Randy Craven, MD, discusses the pearls of his presentation, "Biodegradation of Intracameral Bimatoprost Sustained-Release Implant (Bimatoprost SR, Allergan) in a 24-Month, Phase 1/2 Study in Glaucoma Patients," which he shared at the annual 2019 ASCRS meeting in San Diego.

RELATED: Novel compound shows promise for dry eye in proof-of-concept study

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Parag Majmudar, MD, on bridging the gap between residency and real-world practice
Brett Bielory, MD, discusses his poster at the ASCRS annual meeting, which focuses on an under-diagnosed corneal pathology: neurotrophic keratitis.
ASCRS 2025: Eva Kim, MD, discusses implantable collamer lenses and high myopia.
Abby Markward, MBA, and Hattie Hayes, editor of Ophthalmology Times Europe, discuss the ASCRS and ASOA meetings
Abby Markward discusses the ASCRS Foundation and the ASCRS Annual Meeting
(Image credit: Ophthalmology Times) Inside ASCRS 2025: Francis S. Mah, MD, takes the helm with a vision for research, education, and advocacy
(Image credit: Ophthalmology Times) Neda Shamie_Controversies in Modern Eye Care 2025
(Image credit: Ophthalmology Times) AGS 2025: A look at Gemini and the MIGS revolution with Mona Kaleem, MD
© 2025 MJH Life Sciences

All rights reserved.